The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

Common end points for phase II trials in patients with glioblastoma multiforme (GBM) are six-month progression-free survival (PFS6) and 12-month overall survival (OS12). OS12 can be accurately measured but may be confounded with subsequent therapies upon progression, whereas the converse is true for...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ballman, Karla V., Buckner, Jan C., Brown, Paul D., Giannini, Caterina, Flynn, Patrick J., LaPlant, Betsy R., Jaeckle, Kurt A.
Формат: Artigo
Язык:Inglês
Опубликовано: Duke University Press 2007
Предметы:
Clinical Investigations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1828103/
https://ncbi.nlm.nih.gov/pubmed/17108063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2006-025
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы